期刊文献+

普萘洛尔对去卵巢大鼠骨密度及血清白细胞介素6的影响(英文) 被引量:1

Effects of propranolol to bone density and serum interleukin-6 in ovariectomized rats
下载PDF
导出
摘要 背景:交感神经系统影响骨代谢的具体作用和机制不明确。目的:探讨普萘洛尔对去卵巢大鼠骨密度及对血清白细胞介素6(IL-6)水平的影响,研究β受体阻滞剂对骨质疏松的防治作用及机制。设计:随机对照的实验研究。地点、材料和干预:本实验在中国中医研究院基础所完成。将50只健康雌性未交配6个月龄SD大鼠随机分为5组:①假手术组。②去卵巢(OVX)后雌激素治疗(O+E)组。③OVX后普萘洛尔治疗(O+P)组。④OVX后雌激素+普萘洛尔治疗(O+E+P)组。⑤OVX后安慰剂(OVX)组。OVX后1周开始经灌胃给予普萘洛尔、皮下注射17β-雌二醇,共12周。动物处死时留取第3~5腰椎、血清标本,进行骨密度分析及血清IL-6水平测定。主要观察指标:各组大鼠椎骨骨密度及血清瘦素水平。结果:O+P,O+P+E,O+E组的骨密度较OVX组明显增高(P<0.05),血清IL-6水平OVX组犤(336.6±18.1)ng/L犦较假手术组犤(208.8±17.2)ng/L犦明显增高(t=16.982,P<0.01),O+E组犤(252.7±16.3)ng/L犦,O+P组犤(274.4±20.0)ng/L犦,O+P+E组犤(222.9±16.5)ng/L犦均明显低于OVX组犤(336.6±18.1)ng/L犦(t=11.160,7.783,14.971,P<0.01)。结论:普萘洛尔能使卵巢切除术后骨质疏松大鼠的骨密度改善,能有效地预防OVI大鼠的骨丢失,同时降低血清水平。 BACKGROUND:The mechanism how the sympathetic nervous system affects bone metab olism remains unclear. OBJECTIVE:To explore the effects of propranolol to bone density and serum inte rleukin-6 in ovariectomized rats and to study the preventive function and mecha nism of βreceptor blocking agent to osteoporosis. DESIGN:Randomized case-control trial study. SETTING,PARTICIPANTS and INTERVENTIONS:The study was done in Foundamental Rese arch Institution of Academy of Traditional Chinese Medicine.Fifty 6-month-old unmated female SD rats were randomly divided into 5 groups:sham operated group,o variectomized and treated with estrogen group(O+E),ovariectomized and treated w ith propranolol group(O+P),ovariectomized and treated with both estrogen and pr opranolol group(O+E+P),ovariectomized and treated with placebo group(OVX). Pro pranolol was infused to stomach and 17 β-estradiol was given subcutaneously fr om the first week after ovariectomy for 12 weeks.The 3-5 lumbar vertebras and b lood serum samples were collected to do the bone density analysis and assay of s erum interleukin-6(IL-6). MAIN OUTCOME MEASURES:Spinal bone density and the values of serum IL-6 in ea ch group. RESULTS:The bone densities in the O+P,O+P+E and O+E groups were much high er than that of the OVX(P< 0.05),the serum IL-6 in the OVX group[(336.6±18.1) ng/L] was higher than that in the sham operated group[(208.8±17.2) ng/L](t=16.9 82,P< 0.01) and was also higher than those in the O+E[(252.7±16.3) ng/L],O+P[ (274.4±20.0)ng/L] and O+P+E[(222.9±16.5)ng/L] groups(t=11.160,7.783,14.971,P < 0.01). CONCLUSION:Propranolol could improve the bone density in ovariectomized rats suffered from osteoporosis and efficiently prevent the bone loss and reduce the level of serum IL-6 simultaneously.
出处 《中国临床康复》 CSCD 2004年第15期2988-2989,共2页 Chinese Journal of Clinical Rehabilitation
基金 卫生部国际交流中心默沙东基金资助(19980216)~~
  • 相关文献

参考文献4

二级参考文献60

  • 1Simpson RJ,Hammacber A,Smith DK,Matthew JM,Ward LD,et al.Interleukin-6:Structure-function relationships.Protein Sci 1997;6(5): 929 - 95 [ Review ].
  • 2Manolagas SC,Jilka RL.Bone marrow,cytokines,and bone remodeling.Emerging insights into the pathophysiology of osteoporosis.N Engl J Med 1995;332(5):305-11[Review].
  • 3Bellido T,Stahl N,Farruggella TJ,Borba V,Yancopoulos GD,Manolagas SC.Detection of receptors for interleukin-6,interleukin-11,leukemis inhibitory factor,oncostatin M,and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells.J Clin Invest 1996;97(2):431-7.
  • 4Vermes C,Jacobs JJ,Zhang J,Fimeisz G,Roebuck KA,Glant TT.Shedding of the Interleukin-6(IL-6)Receptor(gp80)Determines the Ability of IL-6 to Induce gp130 Phosphorylation in Human Oateoblasts.J Biol Chem 2002;277(19):16879-87.
  • 5Friedericbs K, Schmitz J, Weisseubach M, Heinrich PC, Schaper F. Intedeukin-6-induced proliferation of pre-B cells mediated by receptor complexce htcking the SHP2/SOCS3 recruitment sites revisited. Eur J Biochem 2001:268 (24): 6401 - 7.
  • 6Kurotani R, Yasuda M, Oyama K, et al. Expression of interleukin-6, intedeukin-6 receptor (gp80), and the receptor's signal-transducing subunit (gp130) in human normal pituitary glands and pituitary adenomas. Mod Pathol 2001 ; 14 (8) : 791 - 7.
  • 7Montero-Julian FA.The soluble IL-6 receptors:serum levels and biological function.Cell Mol Biol(Noisy-le-grand) 2001;47(4):583-97.
  • 8Auernhammer C J, Melmed S. Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev 2000; 21 (3) : 313 - 4.5.
  • 9Gomez-Lechon MJ.Oncostatin M:signal transduction and biological activity,Life Sci,1999; 65 (20): 2019 -30.
  • 10Sleeman MW,Anderson KD,Lambert PD,Yancopoulos GD,Wiegand SJ,The ciliary neurotrophic factor and its receptor,CNTFR alpha.Pharm Acta Helv 2000;74(2-3):265-72[Review].

共引文献49

同被引文献5

  • 1Flier JS.Physiology:is brain sympathetic to bone?Nature 2002;420(6916):619,621-22.
  • 2Takeda S,Elefteriou F,Levasseur R,et al.Leptin regulates bone formation via the sympathetic nervous system.Cell2002;111(3):305-17.
  • 3Sseur R,Sabatier JP,Potrel-Burgot C,et al.Sympathetic nervous system as transmitter of mechanical loading in bone.Joint Bone Spine 2003; 70(6):515-9.
  • 4Vongpatanasin W,Tuncel M,Mansour Y,et al.Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women.Circulation 2001;103(24):2903-8.
  • 5张星光,吕肖锋,祖秋,李艳玲.雌激素对去卵巢大鼠血清瘦素的影响[J].中国临床康复,2004,8(12):2320-2321. 被引量:4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部